Kymera Therapeutics Advances KT-621 Development With Phase 2b Enrollment Completion
MT Newswires Live
Jun 25
Kymera Therapeutics (KYMR) has completed enrollment in its phase 2b Broaden2 trial of KT-621 in moderate to severe atopic dermatitis ahead of schedule, the company said Thursday.
Enrollment was completed nearly six months earlier than expected, allowing Kymera to bring forward the topline data readout to year-end 2026 from mid-2027, the company said.
Kymera plans to initiate phase 3 trials in atopic dermatitis by mid-2027 and noted that its phase 2b Breadth trial of KT-621 in eosinophilic asthma is ongoing, with data expected in late 2027, it added.
Shares of the company were up 8.1% in premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.